Education
About Us
Working with TipRanks
Follow Us
Immunic (IMUX)
NASDAQ:IMUX
IMUX Stock Chart & Stats
$0.71
-$0.01(-1.34%)
At close: 4:00 PM EST
$0.71
-$0.01(-1.34%)
Day’s Range― - ―
52-Week Range$0.51 - $1.39
Previous CloseN/A
Volume261.21K
Average Volume (3M)1.38M
Market Cap
$74.58M
Enterprise Value$35.02M
Total Cash (Recent Filing)$35.13M
Total Debt (Recent Filing)$126.00K
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding120,284,720
10 Day Avg. Volume1,287,500
30 Day Avg. Volume1,382,240
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.18
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.00K
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$4.67Price Target Upside557.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$12.50M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2 CALLIPER showed statistically significant improvement in confirmed disability for progressive multiple sclerosis and EMPhASIS long-term data reported high rates of patients free from confirmed disability worsening, supporting potential benefit in difficult-to-treat patients.
Intellectual Property And Partnership PotentialPatent protection extending into 2041 and increased attention after competitor setbacks could attract partnerships to expand development into additional indications and add commercial upside beyond core MS studies.
Mechanism And Safety ProfileVidofludimus calcium combines DHODH inhibition to reduce relapses with Nurr1 activation that may protect neurons, and its profile does not require routine liver monitoring like some comparator DHODH agents, suggesting a differentiated tolerability advantage.
Bears Say
Financing And Execution RiskLimited internal funding creates a bottleneck for advancing the drug beyond pivotal studies, making external financing or partnerships essential and increasing the risk of delays or program disruption if capital is not secured.
Market Differentiation RiskUncertainty exists about how vidofludimus calcium will clearly differentiate from numerous established and emerging multiple sclerosis therapies, which could limit physician adoption even if trial signals remain positive.
Valuation PressureAnalyst reduction of the price target after a share count adjustment signals near-term valuation pressure and potential downside for the stock until clear clinical or financing milestones are achieved.
Immunic News
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $0.51 and its highest was $1.39 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $74.58M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is May 07, 2026 which is in 85 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Nov 13, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.143 by $0.013.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunic have?
Immunic has 120,284,720 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.143. Following the earnings report the stock price went down -6.192%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (557.75% Upside)
$4.67 (557.75% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.62%
12-Months-Change
Fundamentals
Return on Equity
-398.50%
Trailing 12-Months
Asset Growth
-37.15%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
IMUX Stock 12 Month Forecast
Average Price Target
$4.67
▲(557.75% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
1.05% Insiders
3.93% Mutual Funds
<0.01% Other Institutional Investors
91.83% Public Companies and Individual Investors